<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124158</url>
  </required_header>
  <id_info>
    <org_study_id>R-2021-902-025</org_study_id>
    <nct_id>NCT05124158</nct_id>
  </id_info>
  <brief_title>COVID-19 Severity and Psychiatric Morbidity</brief_title>
  <official_title>Association of the Severity of the Clinical Picture of COVID-19 and Psychiatric Morbidity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Autonoma de Coahuila</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Mexicano del Seguro Social</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19 pandemic represents the most serious global health threat since the Spanish&#xD;
      influenza, with repercussions on physical and mental health. The balance between physical and&#xD;
      mental state is essential when establishing treatment for a critically ill patient and must&#xD;
      be taken into account by health professionals. Therefore, the investigators hypothesize that&#xD;
      there is an association between the severity of the clinical picture of COVID-19 and&#xD;
      psychiatric morbidity.&#xD;
&#xD;
      Objective. Associate the severity of the clinical picture of COVID-19 with psychiatric&#xD;
      morbidity.&#xD;
&#xD;
      Material and method. Hospitalized participants in the COVID respiratory area at the General&#xD;
      Hospital of the Zone will be included. # 51 of GÃ³mez Palacio, Dgo. in the period from October&#xD;
      1, 2021 to March 31, 2022. This is an epidemiological, observational, prospective,&#xD;
      longitudinal, analytical study. Sociodemographic, clinical and psychiatric evaluation data&#xD;
      will be obtained using GMHAT / PC. A statistical analysis will be carried out using&#xD;
      descriptive statistics (frequencies, measures of central tendency and dispersion) and&#xD;
      analytical, to evaluate the association (Chi2) and to evaluate the effect of the intervening&#xD;
      variables (binary logistic regression and multivariate regression). The data will be analyzed&#xD;
      in the SPSS version 21 program.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who meet selection criteria entered into the COVID area will be included in the&#xD;
      period from October 1, 2021 to March 31, 2022. A non-probabilistic convenience sampling will&#xD;
      be carried out, occluding all patients who agree to participate and meet the criteria of&#xD;
      selection.&#xD;
&#xD;
      Patients entering the COVID area will be invited to participate in the study. Participants&#xD;
      will be questioned about the selection criteria, and if they are eligible to be included in&#xD;
      the study, they will be given the letter of informed consent for reading, clarification of&#xD;
      doubts and signature. Each participant will receive a copy of the informed consent letter,&#xD;
      this copy will remain in the COVID area until the participant is discharged. The researcher's&#xD;
      copy will be handled under the biosafety standards established in the institute for materials&#xD;
      and documents in contact with COVID patients.&#xD;
&#xD;
      Information about their general data and conventional medical history will be obtained&#xD;
      through direct questioning and review of the medical record and a brief neuropsychiatric&#xD;
      evaluation will be performed. The severity data of the COVID clinical picture and clinical&#xD;
      evolution will be obtained from the records in the electronic medical record. The evaluation&#xD;
      of psychiatric morbidities using the GMHAT / PC will be carried out later, prior to feeding&#xD;
      the database.&#xD;
&#xD;
      The information obtained will be emptied into an Excel database for subsequent statistical&#xD;
      analysis with the IBM SPSS STATISTICS program. The information of the study will remain&#xD;
      confidential, the identity of the participants will be protected through the use of the&#xD;
      initials of the participant's name. The data collected will be in charge of the researcher&#xD;
      for safekeeping. The management of the information from the data collection sheets will be&#xD;
      organized by folios.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Days</target_duration>
  <primary_outcome>
    <measure>Degree of severity of the clinical picture of COVID-19</measure>
    <time_frame>Duration of hospitalization (20 days)</time_frame>
    <description>Severity of COVID-19 according to the clinical and paraclinical parameters established by the WHO (Mild, Moderate, Severe, Critical)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with depression</measure>
    <time_frame>Duration of hospitalization (20 days)</time_frame>
    <description>According to the result of the psychiatric evaluation using GMHAT/PC: Absent or Present</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with anxiety</measure>
    <time_frame>Evaluation at hospital admission (2 hours)</time_frame>
    <description>According to the result of the psychiatric evaluation using GMHAT/PC: Absent or Present</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with panic disorder</measure>
    <time_frame>Evaluation at hospital admission (2 hours)</time_frame>
    <description>According to the result of the psychiatric evaluation using GMHAT/PC: Absent or Present</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with psychosis</measure>
    <time_frame>Evaluation at hospital admission (2 hours)</time_frame>
    <description>According to the result of the psychiatric evaluation using GMHAT/PC: Absent or Present</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical evolution of the participants measured by clinical and paraclinical parameters</measure>
    <time_frame>Duration of hospitalization (20 days)</time_frame>
    <description>Worsening or improvement of the disease measurable by observable and diagnosable signs and symptoms according to the clinical and paraclinical parameters established by the WHO.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COVID-19</condition>
  <condition>Psychiatric Disorder</condition>
  <arm_group>
    <arm_group_label>Patients with a diagnosis of COVID-19</arm_group_label>
    <description>A directed psychiatric evaluation will be carried out and 1 evaluation instrument will be applied: Global Tool for the Evaluation of Mental Health in Primary Care (GMHAT / PC).&#xD;
The Global Mental Health Assessment Tool / Primary Care (GMHAT / PC) is a computerized, semi-structured clinical interview tool developed to assess and identify mental health problems. The main diagnosis derives from the use of a hierarchical model based on ICD-10. The diagnostic program takes into account the severity of symptoms (moderate to severe). It also generates alternative diagnoses and comorbidity states based on the presence of symptoms of other disorders. In addition, it includes a suicide risk assessment.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Beneficiaries admitted to the COVID respiratory area of HGZ No.51 in the period from&#xD;
        October 01, 2021 to March 31, 2022.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Beneficiaries in the COVID respiratory area of HGZ No.51&#xD;
&#xD;
          -  COVID-19 diagnosis confirmed by PCR.&#xD;
&#xD;
          -  Complete neuropsychiatric medical history data that allows the evaluation of the&#xD;
             psychiatric status using GMHAT / PC&#xD;
&#xD;
          -  Accept to participate in the study and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing neuropsychiatric diseases and under psychiatric medical treatment.&#xD;
&#xD;
          -  History of psychotropic use and / or withdrawal syndrome.&#xD;
&#xD;
          -  Incomplete file data or that do not allow the assessment of the severity of the&#xD;
             clinical picture of COVID-19 upon admission to the respiratory area.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lilia E Luque Esparza, Dra.</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMSS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lilia Edith Luque-Esparza, Dra.</last_name>
    <phone>+528715796441</phone>
    <email>dra.luque@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Ivette RamÃ­rez Gurrola, Dra.</last_name>
    <phone>+528713161825</phone>
    <email>resimssurge@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto MÃ©xicano del Seguro Social</name>
      <address>
        <city>GÃ³mez Palacio</city>
        <state>Durango</state>
        <zip>35025</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilia E Luque Esparza, Dra.</last_name>
      <phone>8715796441</phone>
      <email>dra.luque@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Laura I RamÃ­rez Gurrola, Dra.</last_name>
      <phone>8713161825</phone>
      <email>resimssurge@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dealmy Delgadillo GuzmÃ¡n, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samira MuÃ±os CRUZ, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura E Vargas RodrÃ­guez, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://www.gob.mx/salud/documentos/lineamientos-y-documentos-de-apoyo-en-salud-mental-y-adicciones-ante-el-covid-19</url>
    <description>Secretaria de la Salud. Lineamientos De Respuesta Y De AcciÃ³n En Salud Mental Y Adicciones Para El Apoyo Psicosocial Durante La Pandemia Por Covid-19 En MÃ©xic</description>
  </link>
  <reference>
    <citation>Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021 Jan;93(1):250-256. doi: 10.1002/jmv.26232. Epub 2020 Sep 30. Review.</citation>
    <PMID>32592501</PMID>
  </reference>
  <reference>
    <citation>Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, Rajagopal S, Pai AR, Kutty S. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. Front Immunol. 2020 Jul 10;11:1648. doi: 10.3389/fimmu.2020.01648. eCollection 2020.</citation>
    <PMID>32754159</PMID>
  </reference>
  <reference>
    <citation>Sharma BB, Singh S, Sharma VK, Choudhary M, Singh V, Lane S, Lepping P, Krishna M, Copeland J. Psychiatric morbidity in chronic respiratory disorders in an Indian service using GMHAT/PC. Gen Hosp Psychiatry. 2013 Jan-Feb;35(1):39-44. doi: 10.1016/j.genhosppsych.2012.09.009. Epub 2012 Oct 31.</citation>
    <PMID>23122486</PMID>
  </reference>
  <reference>
    <citation>Ryerson CJ, Arean PA, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology. 2012 Apr;17(3):525-32. doi: 10.1111/j.1440-1843.2011.02122.x.</citation>
    <PMID>22221976</PMID>
  </reference>
  <reference>
    <citation>Shigemura J, Ursano RJ, Morganstein JC, Kurosawa M, Benedek DM. Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan: Mental health consequences and target populations. Psychiatry Clin Neurosci. 2020 Apr;74(4):281-282. doi: 10.1111/pcn.12988. Epub 2020 Feb 23.</citation>
    <PMID>32034840</PMID>
  </reference>
  <reference>
    <citation>Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, Rubin GJ. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020 Mar 14;395(10227):912-920. doi: 10.1016/S0140-6736(20)30460-8. Epub 2020 Feb 26. Review.</citation>
    <PMID>32112714</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Mexicano del Seguro Social</investigator_affiliation>
    <investigator_full_name>Lilia Edith Luque Esparza</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Psychiatric morbidity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This item has not yet been defined.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

